



# Financial Tear Sheet

## CORPORATE PROFILE

Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.

## PRIMARY IR CONTACT


E-mail: [ir@motifbio.com](mailto:ir@motifbio.com)

## STOCK DETAILS

MTFB (ADS)	
<b>Exchange</b>	NASDAQ GS (US Dollar)
<b>Price</b>	<b>\$1.96</b>
<b>Change (%)</b>	▼ 0.24 (10.91%)
<b>Volume</b>	412,114
<b>52 Week Low</b>	\$2.01
<b>Market Cap</b>	\$
<b>Rolling EPS</b>	0.00
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	

Data as of February 20, 2019 12:33 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



# RECENT NEWS & UPCOMING EVENTS

February 19, 2019

There are currently no events scheduled.

Motif Bio Conference Call and Webcast

February 18, 2019

Motif BioSciences Enters into Amendment Agreement with

Hercules Capital

February 14, 2019

Motif Bio Receives Complete Response Letter from the FDA

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
February 19, 2019	6-K
February 15, 2019	SC 13D/A
February 14, 2019	6-K
February 13, 2019	SC 13G/A